Abstract
Pulmonary vaccine delivery has gained increasing attention during the last decade. This vaccination method has advantages other than parenteral vaccination such as it omits the application of needle. The appropriate formulation of antigens can result improved stability complications associated with conventional vaccines. Antigens formulated as nano carriers reach the respiratory airways of the lungs providing greater chance of uptake by relevant immune cells. These advances promise to accelerate the development and testing of new pulmonary vaccines against many human diseases.